Limited Benefit of Postexposure Prophylaxis With VSV-EBOV in Ebola Virus-Infected Rhesus Macaques.
Limited Benefit of Postexposure Prophylaxis With VSV-EBOV in Ebola Virus-Infected Rhesus Macaques.
复制标题
在感染埃博拉病毒的恒河猴中使用 VSV-EBOV 进行暴露后预防的效果有限。
DOI：
10.1093/infdis/jiad280
复制
发表时间：
2023
期刊：
影响因子：
--
通讯作者：
Feldmann,Heinz
中科院分区：
文献类型：
--
作者：
Bushmaker,Trenton;Feldmann,Friederike;Lovaglio,Jamie;Saturday,Greg;Griffin,AmandaJ;O'Donnell,KyleL;Strong,JamesE;Sprecher,Armand;Kobinger,Gary;Geisbert,ThomasW;Marzi,Andrea;Feldmann,Heinz
水泡性口炎病毒-埃博拉病毒（VSV-EBOV）疫苗已成功用于EBOV疾病爆发期间的环形疫苗接种方法，证明其在短期预防性疫苗接种中的一般益处，但缺乏其在人类真正的暴露后预防（PEP）中的益处的实际证据。动物研究表明，当在致死性EBOV攻击的数小时内使用VSV-EBOV时，PEP有效。在这里，我们使用较低的EBOV攻击剂量和组合的静脉内和肌内VSV-EBOV施用来改善恒河猴模型中的PEP功效。EBOV攻击后1小时的VSV-EBOV治疗导致疾病进展延迟，但结果获益甚微。因此，我们不能证实先前的结果，这些结果表明在非人灵长类动物模型中VSV-EBOV对EBOV PEP的益处是可疑的。
Vesicular stomatitis virus–Ebola virus (VSV-EBOV) vaccine has been successfully used in ring vaccination approaches during EBOV disease outbreaks demonstrating its general benefit in short-term prophylactic vaccination, but actual proof of its benefit in true postexposure prophylaxis (PEP) for humans is missing. Animal studies have indicated PEP efficacy when VSV-EBOV was used within hours of lethal EBOV challenge. Here, we used a lower EBOV challenge dose and a combined intravenous and intramuscular VSV-EBOV administration to improve PEP efficacy in the rhesus macaque model. VSV-EBOV treatment 1 hour after EBOV challenge resulted in delayed disease progression but little benefit in outcome. Thus, we could not confirm previous results indicating questionable benefit of VSV-EBOV for EBOV PEP in a nonhuman primate model.